MedTrace Logo

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

NCT01240967 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2014-03-17

No results posted yet for this study

Summary

The purpose of this study is to compare the absorption and distribution of a single oral dose of TC-5214 in subjects with renal impairment and with subjects with normal renal function.

Conditions

  • Healthy Volunteers
  • Patients
  • Pharmacokinetics
  • Renal Impairment

Interventions

DRUG

TC-5214

Oral tablets, single dose

Sponsors & Collaborators

Principal Investigators

  • Hans A Eriksson, MD · AstraZeneca

  • Thomas Marbury, MD · Orlando Clinical Research Center

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01240967 on ClinicalTrials.gov